Compass Therapeutics announced that its Phase 2/3 clinical trial results for tovecimig, a bispecific antibody combined with paclitaxel, in advanced biliary tract cancer will be presented orally at the ESMO Congress 2026 in Madrid. The presentation, led by Dr. Nilofer Azad from Johns Hopkins University, will highlight data from the COMPANION-002 trial assessing the drug's effectiveness. This event marks a significant step in showcasing Compass's oncology pipeline and advancing treatment options for this difficult-to-treat cancer. Further details will be shared at the congress in October 2026.
Pump.fun, a Solana memecoin launchpad, will unlock 6.875 billion PUMP tokens on August 12, 2026, split between the development team and early investors. This unlock follows a larger July event releasing 82.5 billion tokens, raising concerns about sel...
AppLovin reported a 53% year-over-year revenue increase in Q2, maintaining over 75% profit margins, highlighting its rare combination of scale, profitability, and growth. The slight slowdown in sequential growth was due to timing of machine-learning ...
Binance is seeing a major shift in stablecoin liquidity from the Tron network to Ethereum-based networks over the past two weeks. USDT reserves on Tron dropped nearly 50%, from $1.4 billion to $709 million, while USDT and USDC inflows into Ethereum s...
Coinsbuy, a crypto payment processor for businesses, suffered a security breach draining over $7.9 million from wallets on Ethereum and TRON networks. The attacker obscured the theft by converting stolen assets into Monero, a privacy coin that hinder...
Canary Capital’s XRP ETF ended June 2026 with $241.2 million in assets, down $81.6 million from December 2025 despite $82.4 million net capital share inflows. The fund’s XRP holdings rose 31.7% to 231.3 million tokens, but the sharp 43.27% drop in XR...
